Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study-Reference-Cited by-同舟云学术

Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study

Published:2018-01-30 Issue:3 Volume:178 Page:e215-e216
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Girolomoni G.¹,Feldman S.R.²^ORCID,Emery P.³,Ghil J.⁴,Keum J.W.⁴^ORCID,Cheong S.Y.⁴,Hong E.⁴

Affiliation:

1. Section of Dermatology and Venereology; Department of Medicine; University of Verona; Piazzale A Stefani 1 37126 Verona Italy

2. Department of Dermatology; Wake Forest University School of Medicine; Winston-Salem NC 27101 U.S.A.

3. Leeds Institute of Rheumatic and Musculoskeletal Medicine; University of Leeds; Leeds U.K.

4. Samsung Bioepis Co., Ltd; Incheon Republic of Korea

Funder

Samsung Bioepis Co., Ltd

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.16032/fullpdf

Reference8 articles.

1. Hypersensitivity reactions to biological drugs;Corominas;J Investig Allergol Clin Immunol,2014

2. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy;Emery;Ann Rheum Dis,2017

3. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial;Klareskog;Lancet,2004

4. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial;Keystone;Arthritis Rheum,2004

5. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone;Lindenmayer;Int Clin Psychopharmacol,2005

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A chemoenzymatic method for simultaneous profiling N- and O-glycans on glycoproteins using one-pot format;Cell Reports Methods;2024-08

2. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study;The Lancet Rheumatology;2024-07

3. Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment;Expert Review of Pharmacoeconomics & Outcomes Research;2024-02-12

4. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25

5. Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA;Rheumatology;2023-09-06